Jiangsu Lianhuan Pharmaceutical Co Ltd (600513)

Jiangsu Lianhuan Pharmaceutical Co., Ltd., together with its subsidiaries, manufactures and sells pharmaceuticals, preparations, and API products in China and internationally. The company offers clopidogrel bisulfate tablets to prevent atherothrombotic events; doxycycline hydrochloride tablets for upper respiratory tract infections, tonsilitis, biliary tract infections, lymphadenitis, cellulitis, and chronic bronchitis; azithromycin tablets for the treatment of mild to moderate infections caused by susceptible strains of designated microorganisms; milrinone injection for short-term intravenous therapy in patients with acute compensated heart failure; dapoxetine hydrochloride tablets to treat premature ejaculation; tadafil tablets for erectile dysfunction; and bepotastine besilate tablets. It also provides aiplete tablets to treat benign prostatic hyperplasia; ebastine tablets for allergic rhinitis; felodipine tablets for mild to moderate essential hypertension; drotaverine hydrochloride injection to treat smooth muscle spasms caused by gastrointestinal diseases and to relieve dysmenorrhea; danazol suppositories to treat endometriosis; and terfenadine tablets for allergic rhinitis, perennial allergic rhinitis, and acute and chronic urticaria, as well as preparation products, which covers urinary system, antihistamines, cardiovascular drugs, steroid hormones, and antibiotics. In addition, the company engages in the wholesale of chemical raw materials and pharmaceuticals; sale of medical equipment and electronic products; and provision of medical technology research and development, and technological transfer services. It exports its products to Southeast Asia, North America, South America, Europe, New Zealand, Australia, and other countries. Jiangsu Lianhuan Pharmaceutical Co., Ltd. was founded in 1999 and is headquartered in Yangzhou, China.